Cargando…

PB2300: COMPLEMENT ACTIVATION NEGATIVELY AFFECTS THE PLATELET RESPONSE TO THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A PROSPECTIVE COHORT STUDY

Detalles Bibliográficos
Autores principales:	Åkesson, A., Bussel, J. B., Martin, M., Blom, A. M., Klintman, J., Ghanima, W., Zetterberg, E., Garabet, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431509/ http://dx.doi.org/10.1097/01.HS9.0000852028.48324.af

Ejemplares similares

PB2626: THROMBOPOIETIN RECEPTOR AGONISTS FOR RESISTANT THROMBOCYTOPENIA IN PREGNANCY A CASE SERIES AND REVIEW OF LITERATURE
por: Sayed, Gamal, et al.
Publicado: (2023)

PB2618: USE AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: A SINGLE CENTRE EXPERIENCE
por: Martinez, Celia, et al.
Publicado: (2023)

PB2608: THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA (ITP) IN NORWAY IN THE REAL LIFE – ANALYSIS OF THE NOR-ITP REGISTRY
por: Ilicheva, Ekaterina, et al.
Publicado: (2023)

PB2609: 14 YEARS OF EXPERIENCE WITH THROMBOPOIETIN RECEPTOR AGONISTS IN A SINGLE CENTER
por: Garcia-Pallarols, Francesc, et al.
Publicado: (2023)

PB2313: DARATUMUMAB AS A TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA: A PHASE II STUDY WITH SAFETY RUN-IN (THE DART STUDY)
por: Tsykunova, G., et al.
Publicado: (2022)

PB2425: EFFICACY AND SAFETY OF COMBINED THERAPY OF RECOMBINANT HUMAN THROMBOPOIETIN AND ELTROMBOPAG FOR TREATMENT OF PERSISTENT THROMBOCYTOPENIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pan, Pan, et al.
Publicado: (2023)

Thrombopoietin receptor agonists: ten years later
por: Ghanima, Waleed, et al.
Publicado: (2019)

PB2585: IS THROMBOCYTOPENIA WITH INCREASED IMMATURE PLATELET FRACTION [IPF] IN ICU PATIENTS,A BAD PROGNOSIS?
por: Lourenco, Enna Maria, et al.
Publicado: (2023)

PB2614: MISDIAGNOSIS OF PRIMARY IMMUNE THROMBOCYTOPENIA IN THE COMMUNITY SETTING AND ITS ASSOCIATION WITH INHERITED PLATELET DISORDERS: REPORTING NEW VARIANTS OF INHERITED PLATELET DISORDERS
por: Lara-Martinez, Hugo, et al.
Publicado: (2023)

PB2306: RELAPSE OF IMMUNE THROMBOCYTOPENIA AND MYOCARDITIS
por: Kapsouli, F., et al.
Publicado: (2022)

PB2300: IMPACT OF INITIAL CHEMOTHERAPY CYCLES AND CLINICAL CHARACTERISTICS ON OUTCOMES FOR HIV-ASSOCIATED DIFFUSE LARGE B CELL LYMPHOMA PATIENTS: THE CENTRAL AND WESTERN CHINA AIDS LYMPHOMA LEAGUE STUDY
por: Wang, Chaoyu, et al.
Publicado: (2023)

PB2302: HEPARIN-INDUCED THROMBOCYTOPENIA ANTIBODIES CAN MAINTAIN PLATELET-ACTIVATING PROPERTIES AFTER TWO SESSIONS OF THERAPEUTIC PLASMA EXCHANGE
por: Gkalea, V., et al.
Publicado: (2022)

PB2303: THROMBOCYTOPENIA IN COVID-19 PATIENTS ON ECMO SUPPORT
por: Jones, C., et al.
Publicado: (2022)

PB2685: QUALITY OF LIFE IN INDIAN ADULTS WITH IMMUNE THROMBOCYTOPENIA
por: Bhat, Vivek, et al.
Publicado: (2023)

PB2636: VAYHIT1: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VERSUS PLACEBO IN ADDITION TO FIRST-LINE CORTICOSTEROIDS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
por: Cooper, Nichola, et al.
Publicado: (2023)

PB2637: OUR EXPERIENCE WITH AVATROMBOPAG TREATMENT IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Cervinek, Libor
Publicado: (2023)

PB2623: AVATROMBOPAG FOR THE TREATMENT OF CHILDREN WITH PERSISTENT AND CHRONIC IMMUNE THROMBOCYTOPENIA
por: An, Qi, et al.
Publicado: (2023)

PB2066: SYSTEMIC LUPUS ERYTHEMATOSUS-INDUCED AMEGAKARYOCYTIC THROMBOCYTOPENIA AND SUBSEQUENT APLASTIC ANEMIA
por: Seong, Gyuhee, et al.
Publicado: (2023)

PB2625: VAYHIT2: A RANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF IANALUMAB VS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO FAILED FIRST-LINE STEROID TREATMENT
por: Zaja, Francesco, et al.
Publicado: (2023)

PB2606: REAL-WORLD EXPERIENCE OF HETROMBOPAG IN RELAPSE AND REFRACTORY IMMUNE THROMBOCYTOPENIA
por: Feng, Yimei, et al.
Publicado: (2023)

PB2301: PEDIATRIC IMMUNE THROMBOCYTOPENIA; A GLANCE AT PATIENTS AND CURRENT THERAPEUTIC CHALLENGES
por: Al-Jadiry, M., et al.
Publicado: (2022)

PB2596: OPTIMIZING PLATELET TRANSFUSION FOR CLINICAL PRACTICE. DO PLATELETS AGE MATTER FOR THERAPEUTIC PLATELETS TRANSFUSION?
por: Attallah, Samy, et al.
Publicado: (2023)

PB2635: FEATURES OF PLATELET PATHOLOGY IN PREGNANT WOMEN
por: Zaynutdinova, Dilafruz, et al.
Publicado: (2023)

PB2639: CHANGES IN PLATELETS IN CHRONIC LIVER DISEASES
por: Nuriddinova, Nodira
Publicado: (2023)

PB2194: ISCHEMIC STROKE IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pérez Raya, M., et al.
Publicado: (2022)

PB2294: CHEMOTHERAPY INDUCED THROMBOCYTOPENIA AND ITS ASSOCITAION WITH COAGULOPATHY; A SINGLE CENTRE EXPERIENCE
por: ANWAR, N., et al.
Publicado: (2022)

PB2613: PREDICTIVE MODEL TO EVALUATE THE RISK OF IMMUNE THROMBOCYTOPENIA IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
por: Cornudella, Jesus, et al.
Publicado: (2023)

PB2621: TREATMENT OF IMMUNE THROMBOCYTOPENIA WITH HETROMBOPAG—A SINGLE-CENTER RETROSPECTIVE, OBSERVATIONAL STUDY
por: Zhou, Hu, et al.
Publicado: (2023)

PB2616: SYSTEMIC LUPUS ERYTHEMATOSUS RELATED IMMUNE THROMBOCYTOPENIA: A CHARACTERISTIC CLINICAL FENOTIPE
por: Cornudella, Jesus, et al.
Publicado: (2023)

Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia
por: Bastida, José María, et al.
Publicado: (2021)

PB2299: CLINICAL AND LABORATORY CHARACTERISTICS OF CHILDREN WITH INHERITED THROMBOCYTOPENIA IN A SINGLE EGYPTIAN UNIVERSITY HOSPITAL
por: El Chazli, Y., et al.
Publicado: (2022)

PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA
por: Mcdonald, Vickie, et al.
Publicado: (2023)

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2019)

P1666: EFFECT OF AGONISTS TO THROMBOPOIETIN RECEPTORS ON PLATELET GLYCOME OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA
por: Monzón Manzano, E., et al.
Publicado: (2022)

PB2468: A RETROSPECTIVE STUDY OF ELTROMBOPAG IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: MA, Liangming, et al.
Publicado: (2023)

PB2607: OBESITY IMPAIRS RESPONSE TO FIRST-LINE HIGH-DOSE DEXAMETHASONE IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA.
por: Feng, Gege, et al.
Publicado: (2023)

PB2316: EFFICACY AND SAFETY OF ELTROMBOPAG IN PEDIATRIC PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA AND ITS EFFECT ON CELLULAR IMMUNE FUNCTION
por: 吴, ?.
Publicado: (2022)

PB2670: EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
por: Oliva, Esther, et al.
Publicado: (2023)

PB2628: EXPERIENCE AT THE GUADALAJARA UNIVERSITY HOSPITAL (SPAIN) IN FETAL AND NEONATAL ALLOINMUNE THROMBOCYTOPENIA (FNAIT) DURING EIGHT YEARS.
por: López, María Irene Nuevo, et al.
Publicado: (2023)

Use of Thrombopoietin Receptor Agonists in Childhood Immune Thrombocytopenia
por: Garzon, Angelica Maria, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ols3d4c78etabfrbrstj8iufba